Results 31 to 40 of about 75,890 (310)

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Plasma inflammatory cytokines and survival of pancreatic cancer patients. [PDF]

, 2018
OBJECTIVES: Inflammation and inflammatory conditions have been associated with pancreatic cancer risk and progression in a number of clinical, epidemiological, and animal model studies.
Babic, A., Barbie, D. A., Brais, L. K., Fuchs, C. S., Kulke, M. H., Morales-Oyarvide, V., Neupane, N. P., Ng, K., Poole, E. M., Rifai, N., Rubinson, D. A., Schnure, N., Welch, M. W., Wolpin, B. M., Wong, K., Yuan, C., Zaman, M. M., Zhang, S.   +17 more
core   +2 more sources

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

Trials, 2011
Background Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis.
Toomey Mary, Walker Melissa, Steinberg Seth M, Langan Russell C, Ripley R Taylor, Pandalai Prakash, Davis Jeremy L, Levy Elliot, Avital Itzhak   +8 more
doaj   +1 more source

Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report

Surgical Case Reports, 2020
Background Pancreatic cancer is a disease with a poor prognosis, requiring multidisciplinary treatment combining chemotherapy and surgery for effective management.
Yoshiki Murase, Daisuke Ban, Aya Maekawa, Shuichi Watanabe, Yoshiya Ishikawa, Keiichi Akahoshi, Kosuke Ogawa, Hiroaki Ono, Atsushi Kudo, Toshifumi Kudo, Shinji Tanaka, Minoru Tanabe   +11 more
doaj   +1 more source

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study

BMC Cancer, 2020
Background The current study aimed to evaluate the outcomes of patients with unresectable non-metastatic locally advanced pancreatic adenocarcinoma (LAPA) who did not benefit from resection considering the treatment strategy in the clinical settings ...
Jonathan Garnier, Jacques Ewald, Ugo Marchese, Marine Gilabert, Simon Launay, Laurence Moureau-Zabotto, Flora Poizat, Marc Giovannini, Jean-Robert Delpero, Olivier Turrini   +9 more
doaj   +1 more source

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study

BMC Cancer, 2021
Background Pancreatic ductal adenocarcinoma (PDAC) is still a highly fatal malignancy among the most common cancers. More powerful treatments are expecting to bring hope for patients.
Chen Chang, Xiaofen Li, Dan Cao
doaj   +1 more source

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer [PDF]

, 2013
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.
Bria, E., Cognetti, F., Gamucci, T., Gelibter, A., Mansueto, G., Milella, M., Moscetti, L., Ruggeri, E. M., Sperduti, I., Vaccaro, V.   +9 more
core   +1 more source

The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline

Canadian Journal of Gastroenterology, 2003
BACKGROUND: Pancreatic adenocarcinoma is the fourth most common cause of adult cancer death. About 50% of patients present with metastatic disease, 20% with resectable disease and the remaining 30% of patients are diagnosed with incurable, locally ...
Craig C Earle, Olusegun Agboola, Jean Maroun, Lisa Zuraw, Cancer Care Ontario Practice Guidelines Initiative’s Gastrointestinal Cancer Disease Site Group   +4 more
doaj   +1 more source

Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer

Journal of Pancreatology, 2019
. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Only 15% to 20% of patients present with a primarily resectable tumor at the time of diagnosis.
Lingdi Yin, MD, Yi Miao, MD, PhD, Jun Yu, MD, PhD   +2 more
doaj   +1 more source

Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?

BMC Surgery, 2023
Background The treatment of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) has evolved with a wider application of neoadjuvant chemotherapy (NACHT).
Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Niki Rashidian, Kobe Van Hove, Lambertine Maertens, Suzane Ribeiro, Anne Hoorens, Frederik Berrevoet   +7 more
doaj   +1 more source